Ensysce Biosciences, Inc. (ENSC): Capital Expenditures
$123.6K
Year ended 2025-12-31
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $123.6K | n/a | 2026-03-30, From 2025-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $123.6K | n/a |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $0 | -100.0% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $59.3K | +54.4% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $518.0K | -97.1% |
| Immunome Inc. (IMNM) | 2025-12-31 | $9.69M | +35.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $552.0K | -66.6% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $0 | -100.0% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $279.0K | -36.7% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $799.0K | -74.0% |
Compare ENSC, PRPH, CPHI, KRRO side by side · Screen every company in Pharmaceutical Preparations ↗